TW202126294A - 小分子PI4KIIIα抑制劑組合物、其製備方法及用途 - Google Patents

小分子PI4KIIIα抑制劑組合物、其製備方法及用途 Download PDF

Info

Publication number
TW202126294A
TW202126294A TW109122503A TW109122503A TW202126294A TW 202126294 A TW202126294 A TW 202126294A TW 109122503 A TW109122503 A TW 109122503A TW 109122503 A TW109122503 A TW 109122503A TW 202126294 A TW202126294 A TW 202126294A
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
composition according
oil
pao
group
Prior art date
Application number
TW109122503A
Other languages
English (en)
Chinese (zh)
Inventor
福德 黃
峰 王
書 楊
常平 焦
Original Assignee
大陸商挪貝肽醫藥科技(上海)有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商挪貝肽醫藥科技(上海)有限公司 filed Critical 大陸商挪貝肽醫藥科技(上海)有限公司
Publication of TW202126294A publication Critical patent/TW202126294A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
TW109122503A 2019-07-05 2020-07-03 小分子PI4KIIIα抑制劑組合物、其製備方法及用途 TW202126294A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
WOPCT/CN2019/094831 2019-07-05
CN2019094831 2019-07-05

Publications (1)

Publication Number Publication Date
TW202126294A true TW202126294A (zh) 2021-07-16

Family

ID=74115038

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109122503A TW202126294A (zh) 2019-07-05 2020-07-03 小分子PI4KIIIα抑制劑組合物、其製備方法及用途

Country Status (15)

Country Link
US (1) US20230115711A1 (cg-RX-API-DMAC7.html)
EP (1) EP3995134A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022538505A (cg-RX-API-DMAC7.html)
KR (1) KR20220071175A (cg-RX-API-DMAC7.html)
CN (2) CN114555056B (cg-RX-API-DMAC7.html)
AU (1) AU2020309681A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022000155A2 (cg-RX-API-DMAC7.html)
CA (1) CA3149104A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022001218A2 (cg-RX-API-DMAC7.html)
IL (1) IL289586A (cg-RX-API-DMAC7.html)
MX (1) MX2022000287A (cg-RX-API-DMAC7.html)
PE (1) PE20220942A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022550254A1 (cg-RX-API-DMAC7.html)
TW (1) TW202126294A (cg-RX-API-DMAC7.html)
WO (1) WO2021004422A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114685566A (zh) * 2020-12-31 2022-07-01 江苏挪贝肽医药科技有限公司 氧化苯砷晶型i、晶型ii和晶型iii及其制备方法
MX2024004055A (es) * 2021-09-30 2024-06-19 Nuo Beta Pharmaceutical Tech Shanghai Co Ltd Compuesto de oxido de fenilarsina halogenado y aplicacion del mismo.
CN116478954B (zh) * 2023-02-14 2025-06-10 中国农业大学 水稻基因OsPI4K及其在水稻抗稻瘟病中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002365110A1 (en) * 2001-07-10 2003-07-15 Massachusetts Institute Of Technology Small molecule microarrays
EP2319926B1 (en) * 2007-07-05 2016-08-31 Arrowhead Research Corporation DSRNA for treating viral infection
WO2016172952A1 (zh) * 2015-04-30 2016-11-03 江苏挪贝肽医药科技有限公司 PI4KIIIα蛋白及相关的膜蛋白复合体在治疗阿尔茨海默病中的应用
WO2019200043A1 (en) * 2018-04-11 2019-10-17 New Mexico Tech University Research Park Coporation Lipid prodrugs for use in drug delivery
EP4130014A4 (en) * 2020-03-31 2024-05-15 Nuo-Beta Pharmaceutical Technology (Shanghai) Co., Ltd. Deuterated oxophenylarsine compound and use thereof
MX2024004055A (es) * 2021-09-30 2024-06-19 Nuo Beta Pharmaceutical Tech Shanghai Co Ltd Compuesto de oxido de fenilarsina halogenado y aplicacion del mismo.

Also Published As

Publication number Publication date
KR20220071175A (ko) 2022-05-31
CN118105372A (zh) 2024-05-31
EP3995134A4 (en) 2023-07-12
WO2021004422A1 (zh) 2021-01-14
JP2022538505A (ja) 2022-09-02
IL289586A (en) 2022-03-01
EP3995134A1 (en) 2022-05-11
CA3149104A1 (en) 2021-01-14
CN114555056B (zh) 2024-01-05
AU2020309681A1 (en) 2022-02-24
BR112022000155A2 (pt) 2022-04-12
PE20220942A1 (es) 2022-05-31
US20230115711A1 (en) 2023-04-13
CO2022001218A2 (es) 2022-05-20
PH12022550254A1 (en) 2023-06-26
MX2022000287A (es) 2022-06-16
CN114555056A (zh) 2022-05-27

Similar Documents

Publication Publication Date Title
CA2824317C (en) Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
KR101651448B1 (ko) 체지방을 국소적으로 증가시키는 방법 및 조성물
SK279845B6 (sk) Farmaceutický prostriedok, spôsob jeho prípravy a
JP2014513094A (ja) 親油性医薬用薬剤の改良された非経口製剤ならびにそれを調製および使用するための方法
BR112015015870B1 (pt) Uso de uma composição farmacêutica
BG61637B1 (bg) Състав за трансдермално приложение,съдържащ селегилин,и метод за получаването му
JP6852204B2 (ja) 低水溶性薬剤の低融解イオン性塩の組成物および調製方法
CN114980890B (zh) 可注射长效镇痛药物组合物及其制备方法和用途
CN114555056B (zh) 小分子PI4KIIIα抑制剂组合物、其制备方法及用途
BR112020010519A2 (pt) formulação farmacêutica de oxima de 3¿lfa-etinil-3¿eta-hidroxiandrostan-17-ona
JP2007510737A (ja) 癌処置のためのセラミド異化阻害剤としてのppmp
CN1529590A (zh) 治疗与新血管生成相关疾病的组合物及方法
EP3285755B1 (en) Creatine hydrochloride for the treatment of huntington's disease
WO2015110040A1 (zh) 苯丁酸氮芥衍生物、制备方法及应用
CN108310390B (zh) 多西他赛亚油酸酯及其脂肪乳剂和应用
CN108309935B (zh) 一种紫檀芪类化合物心肌靶向制剂及其应用
HK40074190B (en) MICROMOLECULE PI4KIIIα INHIBITOR COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF
CN104945269A (zh) 一种大黄酸羧酸酯类衍生物及其应用
CN109985004A (zh) 氟比洛芬酯脂肪乳注射液、其制备方法及应用
HK40074190A (en) MICROMOLECULE PI4KIIIα INHIBITOR COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF
HK40073830A (en) Micromolecule pi4kiiialpha inhibitor composition, preparation method therefor and use thereof
OA20568A (en) Micromolecule PI4Klllα inhibitor composition, preparation method therefor and use thereof.
JP7440939B2 (ja) イブプロフェンエステル系プロドラッグ、医薬組成物、調製方法および使用
CN103313697A (zh) 激酶抑制剂的口服制剂
EP1648413B1 (en) Pharmaceutical compositions of short-acting sedative hypnotic agent